Compugen (CGEN) Price/OCF Ratio: History & Chart

Compugen Ltd.(CGEN)

Biotechnology · Holon, TA

$2.28-0.03 (-1.34%)

Delayed quote: Oct 6, 2026, 10:15 AM EDT

About Compugen Ltd.

Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors. COM902, a therapeutic antibody designed to target TIGIT, which is also in Phase I clinical trials as a monotherapy for advanced malignancies. Bapotulimab, an antibody targeting ILDR2, presently in Phase I clinical development for solid tumor indications. AZD2936, an innovative bispecific antibody targeting both TIGIT and PD-1, advancing through Phase I/II clinical studies for patients with advanced or metastatic non-small cell lung cancer. Additionally, Compugen maintains earlier-stage immuno-oncology programs, with a particular emphasis on myeloid targets. To further its research and development, Compugen actively fosters strategic alliances. It has a collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics that modulate immune checkpoint regulators. Another key partnership is with Bristol-Myers Squibb, aimed at evaluating the safety and tolerability of COM701 when administered alongside Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. The company also collaborates with Johns Hopkins School of Medicine to investigate novel T cell and myeloid checkpoint targets, and has a distinct research collaboration with Johns Hopkins University specifically dedicated to myeloid science. Furthermore, Compugen holds a licensing agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products.

Holon, TA

75 employees

cgen.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Eran Ophir

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Compugen Ltd. (CGEN)	$215.50M	N/A	N/A	N/A	N/A
Niagen Bioscience Inc (NAGE)vs ›	$214.64M	36.08	45.91	60.75	60.42
Lyell Immunopharma, Inc. (LYEL)vs ›	$213.68M	N/A	N/A	N/A	N/A
Alector, Inc. (ALEC)vs ›	$208.17M	N/A	3.18	3.20	4.43
Electra Therapeutics Inc. (ETRA)vs ›	$200.03M	N/A	N/A	N/A	N/A
Keros Therapeutics, Inc. (KROS)vs ›	$225.04M	N/A	9.04	9.10	9.10
MacroGenics, Inc. (MGNX)vs ›	$229.99M	N/A	62.49	62.49	62.49
Eledon Pharmaceuticals, Inc. (ELDN)vs ›	$191.04M	N/A	N/A	N/A	N/A
BioAge Labs Inc. (BIOA)vs ›	$234.82M	N/A	N/A	N/A	N/A
AN2 Therapeutics, Inc. (ANTX)vs ›	$191.07M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

Compugen Ltd. (CGEN)

$215.50M

N/A

Niagen Bioscience Inc (NAGE)vs ›

$214.64M

36.08

45.91

60.75

60.42

Lyell Immunopharma, Inc. (LYEL)vs ›

$213.68M

N/A

Alector, Inc. (ALEC)vs ›

$208.17M

N/A

3.18

3.20

4.43

Electra Therapeutics Inc. (ETRA)vs ›

$200.03M

N/A

Keros Therapeutics, Inc. (KROS)vs ›

$225.04M

N/A

9.04

9.10

MacroGenics, Inc. (MGNX)vs ›

$229.99M

N/A

62.49

Eledon Pharmaceuticals, Inc. (ELDN)vs ›

$191.04M

N/A

BioAge Labs Inc. (BIOA)vs ›

$234.82M

N/A

AN2 Therapeutics, Inc. (ANTX)vs ›

$191.07M

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

CGEN Price/OCF Ratio Metrics

CGEN Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics